Barrett & Company’s Jazz Pharmaceuticals JAZZ Stock Holding History

Barrett & Company’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.89K	Hold	12	–	–	﹤0.01%	597
2026 Q1	$2.27K	Hold	12	–	–	﹤0.01%	571
2025 Q4	$2.04K	Hold	12	–	–	﹤0.01%	586
2025 Q3	$1.58K	Hold	12	–	–	﹤0.01%	594
2025 Q2	$1.27K	Hold	12	–	–	﹤0.01%	601
2025 Q1	$1.49K	Hold	12	–	–	﹤0.01%	573
2024 Q4	$1.48K	Hold	12	–	–	﹤0.01%	571
2024 Q3	$1.34K	Hold	12	–	–	﹤0.01%	549
2024 Q2	$1.28K	Sell	12 -3	-20%	-$330	﹤0.01%	561
2024 Q1	$1.83K	Hold	15	–	–	﹤0.01%	553
2023 Q4	$1.87K	Hold	15	–	–	﹤0.01%	536
2023 Q3	$1.97K	Buy	15 +3	+25%	+$400	﹤0.01%	547
2023 Q2	$1.49K	Hold	12	–	–	﹤0.01%	548
2023 Q1	$1.76K	Sell	12 -3	-20%	-$444	﹤0.01%	524
2022 Q4	$2.36K	Hold	15	–	–	﹤0.01%	505
2022 Q3	$2.36K	Buy	+15	New	+$2.28K	﹤0.01%	505

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Barrett & Company's JAZZ Position: Q2 2026 in Review

Barrett & Company held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 12 shares worth $2.89K. The position accounts for ﹤0.01% of the portfolio, ranked #597.

Barrett & Company first reported a position in JAZZ in Q3 2022 and has held it in 16 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Barrett & Company held 12 shares of Jazz Pharmaceuticals worth $2.89K as of Q2 2026.
Barrett & Company left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Barrett & Company's portfolio in Q2 2026, its #597 holding.
Barrett & Company first reported a position in Jazz Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Barrett & Company's 13F filing for Q2 2026, filed 24 Jul 2026.